A Study to Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled ZT-111 in Patients With Metastatic Prostate Cancer
This study is to evaluate the safety, biodistribution, radiation dosimetry and tumor uptake of the \[131I\]/\[18F\]/\[68Ga\]ZT-111 in patients with PSMA positive metastatic prostate cancer.
Prostate Specific Membrane Antigen Positive Metastatic Prostate Cancer
RADIATION: [131I]/[18F]/[68Ga]ZT-111
Dosimetry, Whole body and organ uptake activity, About 24hours from time of injection
Incidence and severity of adverse events, Incidence and severity of adverse events (AEs) as assessed by CTCAE v5.0, From administration of [131I]/[18F]/[68Ga]ZT-111 until 1 week after injection
This study is to evaluate the safety, biodistribution, radiation dosimetry and tumor uptake of the \[131I\]/\[18F\]/\[68Ga\]ZT-111 in patients with PSMA positive metastatic prostate cancer.